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therosclerotic renal artery stenosis (ARAS) accounts 
for over a third of all cases of end-stage kidney dis-
ease.1 Furthermore, ARAS represents a common 
manifestation of generalized atherosclerosis and 
is the predominant lesion in the renal arteries of 
patients more than 50 years of age.2 This is not a minor issue, 
considering that older patients have greater risk of comorbid 
disease and mortality, primarily related to cardiovascular events, 
and that ARAS constitutes an independent risk factor for aggra-
vation of cardiovascular disease.3
What constitutes critical renal artery stenosis in the clinical 
setting remains to be determined. Similarly, it remains unclear 
why the kidney affected by ARAS often does not improve or 
continues to deteriorate after successful revascularization. This 
is probably related to greater damage of the ischemic renal 
parenchyma that goes beyond the simple mechanical obstruc-
tion. The severity of the renal structural damage is an impor-
tant determinant and predictor of renal functional outcome 
and mortality in atherosclerotic nephropathy.4
Statins (3-hydroxy-3-methylglutaryl coenzyme A reduct-
ase inhibitors), which have extensive clinical application for 
patients with dyslipidemia and atherosclerosis, enhance renal 
angiogenesis, attenuate intrarenal microvascular remodeling, 
and preserve the function and morphology of the ischemic kid-
ney.5 These renoprotective effects in the ischemic kidney were 
achieved without any decrease in the degree of ARAS, further 
supporting the theory and underscoring the importance of 
protecting the renal parenchyma distal to the obstruction.
In this issue of the American Journal of Hypertension, Silva 
et al. evaluated the role of statin therapy in renal survival and 
overall mortality in patients with ARAS.6 In this 11-year long 
retrospective observational study, the authors confirm former 
reports identifying renal dysfunction due to ARAS as a pre-
dictor of cardiovascular mortality. As a novel finding, Silva 
et al. identified the use of statins as beneficial regarding renal 
function preservation (progression of renal insufficiency: 7.4% 
of S patients (patients who received statin therapy) vs. 38.9% 
of NS patients (patients who had no statin)) and patient sur-
vival (overall mortality: 5.9% in S patients vs. 36.1% in NS 
patients). This finding is important because the indications 
for renal revascularization, and the impact of revasculariza-
tion on blood pressure, renal function, and survival, remain 
controversial. Although this study is limited by a retrospec-
tive study design, a systematic screening for comorbidities and 
conditions was performed. The authors included uniformly 
defined and well-documented variables such as peripheral 
vascular disease, antihypertensive drug regimen and renal 
function at baseline into the statistical models. The impact of 
these variables on patient survival is therefore more reliable 
and in line with findings on patients suffering from coronary 
heart disease (CHD). Interestingly, this is one of the rare stud-
ies published for patients with ARAS including statin into the 
statistical model to determine predictors of improved survival 
and renal function. This result should be confirmed by pro-
spective studies such as the ongoing CORAL (Cardiovascular 
Outcomes in Renal Atherosclerotic Lesions) and ASTRAL 
(Angioplasty and Stenting for Renal Artery Lesions) trials. If 
these beneficial effects of statins are confirmed in patients with 
ARAS, then their use as secondary prevention would not be 
limited to patients suffering from CHD and occlusive cerebral 
artery disease. In summary, this study suggests that in case of 
proven ARAS with or without renal impairment, secondary 
preventive treatment with statin irrespective of the lipid profile 
should be used to slow the progression of renal insufficiency 
and to reduce overall mortality.
Disclosure: the author declared no conflict of interest.
1. Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal 
failure and end-stage renal disease. J Hypertens 1997; 15:1365–1377.
2. Hanzel G, Balon H, Wong O, Soffer D, Lee DT, Safian RD. Prospective evaluation of 
aggressive medical therapy for atherosclerotic renal artery stenosis, with renal 
artery stenting reserved for previously injured heart, brain, or kidney. Am J Cardiol 
2005; 96:1322–1327.
3. Edwards MS, Craven TE, Burke GL, Dean RH, Hansen KJ. Renovascular disease 
and the risk of adverse coronary events in the elderly: a prospective, population-
based study. Arch Intern Med 2005; 165:207–213.
4. Meier P, Rossert J, Plouin PF, Burnier M. Atherosclerotic renovascular disease: 
beyond the renal artery stenosis. Nephrol Dial Transplant 2007; 22:1002–1006.
5. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO. Simvastatin 
promotes angiogenesis and prevents microvascular remodeling in chronic renal 
ischemia. FASEB J 2006; 20:1706–1708.
6. Silva VS, Martin LC, Franco RJS, Carvalho FC, Bregagnollo EA, Castro JH, Gavras I, 
Gavras H. Pleiotropic effects of statins may improve outcomes in atherosclerotic 
renovascular disease.  Am J Hypertens 2008; 21:1163–1168.
1Division of Nephrology, Department of Medicine, Hôpital de Sion, Sion, 
Switzerland. correspondence: Pascal Meier (pascal.meier@chuv.ch)
doi:10.1038/ajh.2008.264
© 2008 American Journal of Hypertension, Ltd.
Statin Therapy in ARAS: Beyond Cholesterol 
Lowering
Pascal Meier1
See article page 1163
